idecabtagene vicleucel for myeloma: karmma study results and real-world evidence
Published 1 year ago • 97 plays • Length 7:01Download video MP4
Download video MP3
Similar videos
-
7:55
real-world car-t outcomes, use of ide-cel, cilta-cel for myeloma
-
5:16
idecabtagene vicleucel in pts with relapsed and refractory multiple myeloma: updated karmma results
-
1:28
real-world experience: ide-cel for r/r multiple myeloma
-
4:10
karmma: idecabtagene vicleucel qol
-
10:18
ide-cel; bb2121, a bcma-targeted car t-cell therapy, in patients with rrmm: initial karmma results
-
4:57
idecabtagene vicleucel for r/r myeloma
-
2:44
real-world safety & efficacy of ide-cel in patients with multiple myeloma
-
16:46
idecabtagene vicleucel for high-risk early relapse multiple myeloma - karmma-2 study
-
14:34
real-world outcomes for patients treated with ide-cel after having received a bcma-targeted therapy
-
6:17
myeloma panel compares real-world versus clinical trial data for car-ts, bispecifics
-
1:40
karmma-3: phase iii trial of idecabtagene vicleucel in r/r myeloma
-
7:03
updated results of the idecabtagene vicleucel (ide-cel bb2121) crb-401 trial in rr multiple myeloma
-
5:34
karmma: idecabtagene vicleucel for r/r mm
-
2:56
combining expert opinion and trial data to predict survival for myeloma patients receiving ide-cel
-
6:12
idecabtagene vicleucel for relapsed and refractory multiple myeloma
-
0:55
ide-cel cart in multiple myeloma
-
2:19
karmma-4: idecabtagene vicleucel in high-risk newly diagnosed multiple myeloma
-
3:20
karmma: idecabtagene vicleucel shows efficacy in high-risk subgroups of r/r myeloma
-
1:53
karmma-4: ide-cel for newly diagnosed high-risk multiple myeloma